Company: BNBX
Filing Date: 2025-12-30
Form Type: 424B3
Source: 0001104659-25-125037
Chunk: 19

Company: BNB PLUS CORP.
Filing Date: 2025-12-30
Form: 424B3
Chunk 19
---
 process of amplifying DNA in living bacterial cells. Once amplified, the DNA must be separated from the living cells and other process contaminants via multiple rounds of purification, adding further complexity and costs. Unlike plasmid-based DNA manufacturing, LineaDNA does not require living cells and instead amplifies DNA via the exponential enzymatic process of PCR. The LineaDNA platform is simple, scalable and can rapidly produce large quantities of DNA with minimal purification steps. Preclinical studies conducted by the Company have shown that LineaDNA is substitutable for plasmid DNA in numerous biotherapeutic applications, including:

| · | DNA       
 vaccines; |

| · | DNA                                                    
 templates to produce RNA, including mRNA therapeutics; |

| · | adoptive                                
 cell therapy (CAR-T) manufacturing; and |

| · | homology-directed                   
 repair (HDR)-mediated gene editing. |

Further, we believe that LineaDNA is also substitutable for plasmid DNA in the following nucleic acid-based therapies:

| · | viral                                                      
 vector manufacturing for in vivo and ex vivo gene editing; |

| · | clustered                                                                           
 regularly interspaced short palindromic repeats-mediated gene therapy (CRISPR); and |

| · | non-viral     
 gene therapy. |

<div align='center'>8</div>

LineaRNAP mRNA therapeutics are produced via a process called in vitro transcription (“IVT”) that requires a DNA template and RNAP as starting materials. Typically, the RNAP is derived from the T7 bacteriophage (“WT-T7”). LineaRNAP is a patented next generation WT-T7-based RNAP engineered with a proprietary DNA-binding domain resulting we believe in high mRNA yields, increased mRNA integrity and reduced double-stranded RNA (dsDNA) contamination as compared to conventional WT-T7. LineaRNAP is engineered for use either as a direct replacement for WT-T7 in conventional IVT workflows or with chemically modified LineaDNA templates and a proprietary reaction buffer, the latter marketed as our LineaIVT platform. Company data shows that when used in conventional IVT systems (either using synthetic DNA or plasmid DNA templates), LineaRNAP results in higher mRNA yields, lower dsRNA contamination and higher mRNA integrity when compared to WT-T7. The Company seeks to commercialize LineaRNAP as a standalone product sold to third parties for use in mRNA production workflows that use either synthetic or plasmid DNA templates. LineaRNAP is produced for the Company under an